Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10557971		
Filing Date		2005-11-17		
First Named Inventor Cons		tant Paul Marie Josef Baggen		
Art Unit		2624		
Examiner Name				
Attamen Dealest Number		ED0300E6		

				U.S	PATENTS			Remove		_
Examiner Cite Initial* Patent Number Kind Code1 Issue Date Name of Patent Number of Code1		tentee or Applicant ument	Releva		Lines where					
	1	6535641	B1	2003-03-18	BAGGENSTO	oss				
	2	6526396	B1	2003-02-25	HIRATSUKA	ET AL				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.		Add		_
			U.S.P	ATENT APPL	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Par of cited Doc	tentee or Applicant ument	Releva	,Columns,I ant Passag s Appear	Lines where les or Relev	an
If you wis	Ĺ	dd additional U.S. Publ	shed Ap	polication citation		•	d buttor	Add		_
					IENI DOCUM	MENIS				
	Cite No	Foreign Document Number ³	Countr Code ²	y Kind	1	Name of Patente Applicant of cited Document	e or	where Rele	or Relevant	Ψ,
Examiner Initial*				y Kind	Publication	Name of Patente Applicant of cited	e or	where Rele Passages	evant or Relevant	Ψ,
Initial*	No 1		Code ²	y Kind i Code	Publication 4 Date	Name of Patente Applicant of cited Document	e or	where Rele Passages	evant or Relevant	Ψ,

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10557971		
iling Date		2005-11-17		
irst Named Inventor Const		tant Paul Marie Josef Baggen		
rt Unit		2624		
xaminer Name				
ttorney Docket Numb	or	ER030056		

		EXAMINER SIGNATURE					
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add					
	3	REPORT BIOMERICS: Vital Signs of Identify, IEEE Spectrum February 1994, pages 22-30					
	2	OSEPH A. O'SULLIVAN, ET AL. Performance Analysis of Physical Signature Authentication, IEEE Vol. 47, No. 7, overmber 2001, pages 3034-3039					
	1	AY R. HOINVILLE, ET AL. Spatial Noise Phenomena of Longitudinal Magnetic Recording Media, IIEEE Vol. 28, No. November 1992, pages 3398-3406.					
Examiner Initials*	Cite No	clude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), ublisher, city and/or country where published.	Т				

A

E

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the how-letter code (WIPO Standard ST.3.). ³ For Japanese patent document, be indication of the year of the report must procedule the serial number of patent document. Afford of document were byte accordate wearhood as included on the document under WFO Standard ST is for document and to obtain a characteristic and the serial number of the patent document.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10557971		
Filing Date		2005-11-17		
First Named Inventor	Const	lant Paul Marie Josef Baggen		
Art Unit		2624		
Examiner Name				
Attorney Docket Numb	or	ER030056		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the	appropriate	selection(s):
---------------	----------	----------	-------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael E. Belk/	Date (YYYY-MM-DD)	2007-05-18
Name/Print	Michael F Relk	Registration Number	33357

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DING YESP IEEE SING COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.